208 results on '"Lopatin, Yuri"'
Number of results to display per page
Search Results
2. From hypertension to heart failure
- Author
-
Manolis, Athanasios J, additional and Lopatin, Yuri, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Liver and gut dysfunction
- Author
-
Lopatin, Yuri, additional and Savarese, Gianluigi, additional
- Published
- 2023
- Full Text
- View/download PDF
4. The impact of the COVID-19 pandemic on heart failure management: Global experience of the OPTIMIZE Heart Failure Care network
- Author
-
Cowie, Martin R., Mourilhe-Rocha, Ricardo, Chang, Hung-Yu, Volterrani, Maurizio, Ban, Ha Ngoc, Campos de Albuquerque, Denilson, Chung, Edward, Fonseca, Cândida, Lopatin, Yuri, Magaña Serrano, José Antonio, Mircheva, Lilyana, Moncada-Paz, Gustavo Adolfo, Pagava, Zurab, Reyes, Eugenio B., Saldarriaga, Clara, Schwartzmann, Pedro, Sim Kheng Leng, David, Trivi, Marcelo, Yotov, Yoto Trifonov, and Zieroth, Shelley
- Published
- 2022
- Full Text
- View/download PDF
5. Effectiveness and Tolerability of Trimetazidine 80 Mg Once Daily in Patients with Stable Angina Uncontrolled with Bisoprolol-Based Therapy: The Modus Vivendi Observational Study
- Author
-
Lopatin, Yuri and Petrova, Parvoleta
- Published
- 2022
- Full Text
- View/download PDF
6. Takotsubo Syndrome: An International Expert Consensus Report on Practical Challenges and Specific Conditions (Part-2: Specific Entities, Risk Stratification and Challenges After Recovery).
- Author
-
Yalta, Kenan, Madias, John E., Kounis, Nicholas G., Y-Hassan, Shams, Polovina, Marija, Altay, Servet, Mebazaa, Alexandre, Yilmaz, Mehmet Birhan, Lopatin, Yuri, Mamas, Mamas A., Gil, Robert J., Thamman, Ritu, Almaghraby, Abdallah, Bozkurt, Biykem, Bajraktari, Gani, Fink, Thomas, Traykov, Vassil, Manzo-Silberman, Stephane, Mirzoyev, Ulvi, and Sokolovic, Sekib
- Subjects
CONSENSUS (Social sciences) ,RISK assessment ,TAKOTSUBO cardiomyopathy ,CONVALESCENCE ,DISEASE relapse ,BIOMARKERS ,DISEASE risk factors ,SYMPTOMS - Abstract
Takotsubo syndrome (TTS) still remains as an enigmatic phenomenon. In particular, long-term challenges (including clinical recurrence and persistent symptoms) and specific entities in the setting of TTS have been the evolving areas of interest. On the other hand, a significant gap still exists regarding the proper risk-stratification of this phenomenon in the short and long terms. The present paper, the second part (part-2) of the consensus report, aims to discuss less well-known aspects of TTS including specific entities, challenges after recovery and risk-stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Takotsubo Syndrome: An International Expert Consensus Report on Practical Challenges and Specific Conditions (Part-1: Diagnostic and Therapeutic Challenges).
- Author
-
Yalta, Kenan, Madias, John E., Kounis, Nicholas G., Y-Hassan, Shams, Polovina, Marija, Altay, Servet, Mebazaa, Alexandre, Yilmaz, Mehmet Birhan, Lopatin, Yuri, Mamas, Mamas A., Gil, Robert J., Thamman, Ritu, Almaghraby, Abdallah, Bozkurt, Biykem, Bajraktari, Gani, Fink, Thomas, Traykov, Vassil, Manzo-Silberman, Stephane, Mirzoyev, Ulvi, and Sokolovic, Sekib
- Subjects
CONSENSUS (Social sciences) ,TAKOTSUBO cardiomyopathy ,ELECTROCARDIOGRAPHY - Abstract
In the recent years, there has been a burgeoning interest in Takotsubo syndrome (TTS), which is renowned as a specific form of reversible myocardial dysfunction. Despite the extensive literature available on TTS, clinicians still face several practical challenges associated with the diagnosis and management of this phenomenon. This potentially results in the underdiagnosis and improper management of TTS in clinical practice. The present paper, the first part (part-1) of the consensus report, aims to cover diagnostic and therapeutic challenges associated with TTS along with certain recommendations to combat these challenges. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial.
- Author
-
Tromp, Jasper, Lam, Carolyn S.P., Alemayehu, Wendimagegn, de Filippi, Christopher R., Melenovský, Vojtěch, Sliwa, Karen, Lopatin, Yuri, Arango, Juan Luis, Bahit, M. Cecilia, Roessig, Lothar, O'Connor, Christopher M., Shah, Palak, Westerhout, Cynthia M., Voors, Adriaan A., Pieske, Burkert, and Armstrong, Paul W.
- Subjects
VENTRICULAR remodeling ,HEART metabolism ,BODY surface area ,HEART failure patients ,VENTRICULAR ejection fraction - Abstract
Aims: Reverse ventricular remodelling, defined as a decrease in left ventricular end‐systolic volume indexed to body surface area (LVESVI) or an increase in left ventricular ejection fraction (LVEF), is associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, the underlying pathophysiological mechanisms remain unclear. Methods and results: We evaluated paired core‐lab assessed echocardiograms and measurements of 92 biomarkers at baseline and 8 months thereafter in 419 participants with HFrEF. Reverse ventricular remodelling was defined as a >5% LVEF increase or >15% LVESVI relative decrease between baseline and 8 months. We evaluated the association between baseline biomarkers and their changes with reverse ventricular remodelling in the prospectively randomized controlled VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial. Of 419 patients (median age 66 [interquartile range 57–74] years, 27.4% women), 206 (49.2%) had reverse ventricular remodelling (either a 5% LVEF increase or a 15% LVESVI decrease). There were no differences in baseline biomarker concentrations between patients with versus those without reverse ventricular remodelling on follow‐up. However, in patients with reverse ventricular remodelling there were significant decreases in biomarkers relating to inflammation and cardiac metabolism; particularly the tumour necrosis factor superfamily member 13B (ratio 0.82, 95% confidence interval [CI] 0.77–0.88), growth differentiation factor‐15 (ratio 0.74, 95% CI 0.66–0.84), and insulin‐like growth factor binding protein 7 (ratio 0.80, 95% CI 0.73–0.88). Conclusions: Reverse ventricular remodelling in patients with HFrEF is associated with a decrease of biomarkers related to inflammation and cardiac metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies
- Author
-
Polovina, Marija, primary, Tschöpe, Carsten, additional, Rosano, Giuseppe, additional, Metra, Marco, additional, Crea, Filippo, additional, Mullens, Wilfried, additional, Bauersachs, Johann, additional, Sliwa, Karen, additional, de Boer, Rudolf A., additional, Farmakis, Dimitrios, additional, Thum, Thomas, additional, Corrado, Domenico, additional, Bayes‐Genis, Antoni, additional, Bozkurt, Biykem, additional, Filippatos, Gerasimos, additional, Keren, Andre, additional, Skouri, Hadi, additional, Moura, Brenda, additional, Volterrani, Maurizio, additional, Abdelhamid, Magdy, additional, Ašanin, Milika, additional, Krljanac, Gordana, additional, Tomić, Milenko, additional, Savarese, Gianluigi, additional, Adamo, Marianna, additional, Lopatin, Yuri, additional, Chioncel, Ovidiu, additional, Coats, Andrew J.S., additional, and Seferović, Petar M., additional
- Published
- 2023
- Full Text
- View/download PDF
10. State‐of‐the‐art document on optimal contemporary management of cardiomyopathies
- Author
-
Seferović, Petar M., primary, Polovina, Marija, additional, Rosano, Giuseppe, additional, Bozkurt, Biykem, additional, Metra, Marco, additional, Heymans, Stephane, additional, Mullens, Wilfried, additional, Bauersachs, Johann, additional, Sliwa, Karen, additional, de Boer, Rudolf A., additional, Farmakis, Dimitrios, additional, Thum, Thomas, additional, Olivotto, Iacopo, additional, Rapezzi, Claudio, additional, Linhart, Aleš, additional, Corrado, Domenico, additional, Tschöpe, Carsten, additional, Milinković, Ivan, additional, Bayes Genis, Antoni, additional, Filippatos, Gerasimos, additional, Keren, Andre, additional, Ašanin, Milika, additional, Krljanac, Gordana, additional, Maksimović, Ružica, additional, Skouri, Hadi, additional, Ben Gal, Tuvia, additional, Moura, Brenda, additional, Volterrani, Maurizio, additional, Abdelhamid, Magdy, additional, Lopatin, Yuri, additional, Chioncel, Ovidiu, additional, and Coats, Andrew J.S., additional
- Published
- 2023
- Full Text
- View/download PDF
11. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program
- Author
-
Lopatin, Yuri M., Cowie, Martin R., Grebennikova, Anna A., Sisakian, Hamayak S., Pagava, Zurab M., Hayrapetyan, Hamlet G., Abdullaev, Timur A., Voronkov, Leonid G., Chesnikova, Anna I., Tseluyko, Vira I., Tarlovskaya, Ekaterina I., Dadashova, Gülnaz M., Berkinbaev, Salim F., Glezer, Maria G., Koziolova, Natalia A., Rakisheva, Amina G., Kipiani, Zviad V., and Kurlyanskaya, Alena K.
- Published
- 2018
- Full Text
- View/download PDF
12. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
- Author
-
Hernandez, Adrian F., Udell, Jacob A., Jones, W. Schuyler, Anker, Stefan D., Petrie, Mark C., Harrington, Josephine, Mattheus, Michaela, Seide, Svenja, Zwiener, Isabella, Amir, Offer, Bahit, M. Cecilia, Bauersachs, Johann, Bayes-Genis, Antoni, Chen, Yundai, Chopra, Vijay K., A. Figtree, Gemma, Ge, Junbo, G. Goodman, Shaun, Gotcheva, Nina, Goto, Shinya, Gasior, Tomasz, Jamal, Waheed, Januzzi, James L., Jeong, Myung Ho, Lopatin, Yuri, Lopes, Renato D., Merkely, Béla, Parikh, Puja B., Parkhomenko, Alexander, Ponikowski, Piotr, Rossello, Xavier, Schou, Morten, Simic, Dragan, Steg, Philippe Gabriel, Szachniewicz, Joanna, van der Meer, Peter, Vinereanu, Dragos, Zieroth, Shelley, Brueckmann, Martina, Sumin, Mikhail, Bhatt, Deepak L., and Butler, Javed
- Published
- 2024
- Full Text
- View/download PDF
13. Effect of ivabradine on central aortic blood pressure in patients with stable coronary artery disease: What do we know?
- Author
-
Lopatin, Yuri M. and Vitale, Cristiana
- Published
- 2016
- Full Text
- View/download PDF
14. Pre‐discharge and early post‐discharge management of patients hospitalized for acute heart failure: a scientific statement by the Heart Failure Association ( HFA ) of the ESC
- Author
-
Metra, Marco, primary, Adamo, Marianna, additional, Tomasoni, Daniela, additional, Mebazaa, Alexandre, additional, Bayes‐Genis, Antoni, additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Bauersachs, Johann, additional, Belenkov, Yuri, additional, Böhm, Michael, additional, Gal, Tuvia Ben, additional, Butler, Javed, additional, Cohen‐Solal, Alain, additional, Filippatos, Gerasimos, additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Jankowska, Ewa A., additional, Lainscak, Mitja, additional, Lopatin, Yuri, additional, Lund, Lars, additional, McDonagh, Theresa, additional, Milicic, Davor, additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Piepoli, Massimo, additional, Polovina, Marija, additional, Ponikowski, Piotr, additional, Rakisheva, Amina, additional, Ristic, Arsen, additional, Savarese, Gianluigi, additional, Seferovic, Petar, additional, Sharma, Rajan, additional, Thum, Thomas, additional, Tocchetti, Carlo G., additional, Van Linthout, Sophie, additional, Vitale, Cristiana, additional, Von Haehling, Stephan, additional, Volterrani, Maurizio, additional, Coats, Andrew JS, additional, Chioncel, Ovidiu, additional, and Rosano, Giuseppe, additional
- Published
- 2023
- Full Text
- View/download PDF
15. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC
- Author
-
Metra, Marco, Adamo, Marianna, Tomasoni, Daniela, Mebazaa, Alexandre, Bayes-Genis, Antoni, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Bauersachs, Johann, Belenkov, Yuri, Boehm, Michael, Gal, Tuvia Ben, Butler, Javed, Cohen-Solal, Alain, Filippatos, Gerasimos, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lopatin, Yuri, Lund, Lars H., McDonagh, Theresa, Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Polovina, Marija, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Thum, Thomas, Tocchetti, Carlo G., Van Linthout, Sophie, Vitale, Cristiana, Von Haehling, Stephan, Volterrani, Maurizio, Coats, Andrew J. S., Chioncel, Ovidiu, Rosano, Giuseppe, Metra, Marco, Adamo, Marianna, Tomasoni, Daniela, Mebazaa, Alexandre, Bayes-Genis, Antoni, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Bauersachs, Johann, Belenkov, Yuri, Boehm, Michael, Gal, Tuvia Ben, Butler, Javed, Cohen-Solal, Alain, Filippatos, Gerasimos, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lopatin, Yuri, Lund, Lars H., McDonagh, Theresa, Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Polovina, Marija, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Thum, Thomas, Tocchetti, Carlo G., Van Linthout, Sophie, Vitale, Cristiana, Von Haehling, Stephan, Volterrani, Maurizio, Coats, Andrew J. S., Chioncel, Ovidiu, and Rosano, Giuseppe
- Abstract
Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked increases in death and rehospitalization rates, which then decline exponentially though they remain higher than in patients without a recent hospitalization. Therefore, optimal management of patients with acute heart failure before discharge and in the early post-discharge phase is critical. First, it may prevent rehospitalizations through the early detection and effective treatment of residual or recurrent congestion, the main manifestation of decompensation. Second, initiation at pre-discharge and titration to target doses in the early post-discharge period, of guideline-directed medical therapy may improve both short- and long-term outcomes. Third, in chronic heart failure, medical treatment is often left unchanged, so the acute heart failure hospitalization presents an opportunity for implementation of therapy. The aim of this scientific statement by the Heart Failure Association of the European Society of Cardiology is to summarize recent findings that have implications for clinical management both in the pre-discharge and the early post-discharge phase after a hospitalization for acute heart failure.
- Published
- 2023
- Full Text
- View/download PDF
16. State-of-the-art document on optimal contemporary management of cardiomyopathies
- Author
-
Seferović, Petar M., Polovina, Marija, Rosano, Giuseppe, Bozkurt, Biykem, Metra, Marco, Heymans, Stephane, Mullens, Wilfried, Bauersachs, Johann, Sliwa, Karen, de Boer, Rudolf A., Farmakis, Dimitrios, Thum, Thomas, Olivotto, Iacopo, Rapezzi, Claudio, Linhart, Aleš, Corrado, Domenico, Tschöpe, Carsten, Milinković, Ivan, Bayes Genis, Antoni, Filippatos, Gerasimos, Keren, Andre, Ašanin, Milika, Krljanac, Gordana, Maksimović, Ružica, Skouri, Hadi, Ben Gal, Tuvia, Moura, Brenda, Volterrani, Maurizio, Abdelhamid, Magdy, Lopatin, Yuri, Chioncel, Ovidiu, Coats, Andrew J.S., Seferović, Petar M., Polovina, Marija, Rosano, Giuseppe, Bozkurt, Biykem, Metra, Marco, Heymans, Stephane, Mullens, Wilfried, Bauersachs, Johann, Sliwa, Karen, de Boer, Rudolf A., Farmakis, Dimitrios, Thum, Thomas, Olivotto, Iacopo, Rapezzi, Claudio, Linhart, Aleš, Corrado, Domenico, Tschöpe, Carsten, Milinković, Ivan, Bayes Genis, Antoni, Filippatos, Gerasimos, Keren, Andre, Ašanin, Milika, Krljanac, Gordana, Maksimović, Ružica, Skouri, Hadi, Ben Gal, Tuvia, Moura, Brenda, Volterrani, Maurizio, Abdelhamid, Magdy, Lopatin, Yuri, Chioncel, Ovidiu, and Coats, Andrew J.S.
- Abstract
Cardiomyopathies represent significant contributors to cardiovascular morbidity and mortality. Over the past decades, a progress has occurred in characterization of the genetic background and major pathophysiological mechanisms, which has been incorporated into a more nuanced diagnostic approach and risk stratification. Furthermore, medications targeting core disease processes and/or their downstream adverse effects have been introduced for several cardiomyopathies. Combined with standard care and prevention of sudden cardiac death, these novel and emerging targeted therapies offer a possibility of improving the outcomes in several cardiomyopathies. Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence-based novel therapeutic concepts and established principles of care, tailored to the individual patient aetiology and clinical presentation of the cardiomyopathy. The scope of the document encompasses contemporary treatment of dilated, hypertrophic, restrictive and arrhythmogenic cardiomyopathy. It was based on an expert consensus reached at the Heart Failure Association online Workshop, held on 18 March 2021.
- Published
- 2023
17. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure:A scientific statement by the Heart Failure Association of the ESC
- Author
-
Metra, Marco, Adamo, Marianna, Tomasoni, Daniela, Mebazaa, Alexandre, Bayes-Genis, Antoni, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Bauersachs, Johann, Belenkov, Yuri, Böhm, Michael, Gal, Tuvia Ben, Butler, Javed, Cohen-Solal, Alain, Filippatos, Gerasimos, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lopatin, Yuri, Lund, Lars H., McDonagh, Theresa, Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Polovina, Marija, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Thum, Thomas, Tocchetti, Carlo G., Van Linthout, Sophie, Vitale, Cristiana, Von Haehling, Stephan, Volterrani, Maurizio, Coats, Andrew J. S., Chioncel, Ovidiu, Rosano, Giuseppe, Metra, Marco, Adamo, Marianna, Tomasoni, Daniela, Mebazaa, Alexandre, Bayes-Genis, Antoni, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Bauersachs, Johann, Belenkov, Yuri, Böhm, Michael, Gal, Tuvia Ben, Butler, Javed, Cohen-Solal, Alain, Filippatos, Gerasimos, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lopatin, Yuri, Lund, Lars H., McDonagh, Theresa, Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Polovina, Marija, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Thum, Thomas, Tocchetti, Carlo G., Van Linthout, Sophie, Vitale, Cristiana, Von Haehling, Stephan, Volterrani, Maurizio, Coats, Andrew J. S., Chioncel, Ovidiu, and Rosano, Giuseppe
- Abstract
Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked increases in death and rehospitalization rates, which then decline exponentially though they remain higher than in patients without a recent hospitalization. Therefore, optimal management of patients with acute heart failure before discharge and in the early post-discharge phase is critical. First, it may prevent rehospitalizations through the early detection and effective treatment of residual or recurrent congestion, the main manifestation of decompensation. Second, initiation at pre-discharge and titration to target doses in the early post-discharge period, of guideline-directed medical therapy may improve both short- and long-term outcomes. Third, in chronic heart failure, medical treatment is often left unchanged, so the acute heart failure hospitalization presents an opportunity for implementation of therapy. The aim of this scientific statement by the Heart Failure Association of the European Society of Cardiology is to summarize recent findings that have implications for clinical management both in the pre-discharge and the early post-discharge phase after a hospitalization for acute heart failure., Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked increases in death and rehospitalization rates, which then decline exponentially though they remain higher than in patients without a recent hospitalization. Therefore, optimal management of patients with acute heart failure before discharge and in the early post-discharge phase is critical. First, it may prevent rehospitalizations through the early detection and effective treatment of residual or recurrent congestion, the main manifestation of decompensation. Second, initiation at pre-discharge and titration to target doses in the early post-discharge period, of guideline-directed medical therapy may improve both short- and long-term outcomes. Third, in chronic heart failure, medical treatment is often left unchanged, so the acute heart failure hospitalization presents an opportunity for implementation of therapy. The aim of this scientific statement by the Heart Failure Association of the European Society of Cardiology is to summarize recent findings that have implications for clinical management both in the pre-discharge and the early post-discharge phase after a hospitalization for acute heart failure.
- Published
- 2023
18. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure
- Author
-
Lopatin, Yuri M., Rosano, Giuseppe M.C., Fragasso, Gabriele, Lopaschuk, Gary D., Seferovic, Petar M., Gowdak, Luis Henrique W., Vinereanu, Dragos, Hamid, Magdy Abdel, Jourdain, Patrick, and Ponikowski, Piotr
- Published
- 2016
- Full Text
- View/download PDF
19. Cardiac remodelling part 2: clinical, imaging and laboratory findings: a review from the Biomarkers Working Group of the Heart Failure Association of the ESC
- Author
-
Aimo, Alberto, Vergaro, Giuseppe, González, Arantxa, Barison, Andrea, Lupón, Josep, Delgado, Victoria, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao‐Pires, Inês, Díez, Javier, Foo, Roger SY, Chan, Mark Yan Yee, Anene‐Nzelu, George C, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Belenkov, Yuri, Gal, Tuvia B, Cohen‐Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H, Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristic, Arsen, Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G, van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew JS, Emdin, Michele, Bayes‐Genis, Antoni, Aimo, Alberto, Vergaro, Giuseppe, González, Arantxa, Barison, Andrea, Lupón, Josep, Delgado, Victoria, Richards, A Mark, de Boer, Rudolf A, Thum, Thoma, Arfsten, Henrike, Hülsmann, Martin, Falcao-Pires, Inê, Díez, Javier, Foo, Roger Sy, Chan, Mark Yan Yee, Anene-Nzelu, George C, Abdelhamid, Magdy, Adamopoulos, Stamati, Anker, Stefan D, Belenkov, Yuri, Gal, Tuvia B, Cohen-Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H, Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristic, Arsen, Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G, van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J, Emdin, Michele, and Bayes-Genis, Antoni
- Subjects
therapies ,biomarker ,heart failure ,imaging ,predictor ,remodelling ,ejection fraction ,clinical - Abstract
In patients with heart failure (HF), the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Biomarker Study Group of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with HFrEF because most studies on cardiac remodelling focused on this setting.
- Published
- 2022
20. Heart failure during the COVID‐19 pandemic: clinical, diagnostic, management, and organizational dilemmas
- Author
-
Palazzuoli, Alberto, primary, Metra, Marco, additional, Collins, Sean P., additional, Adamo, Marianna, additional, Ambrosy, Andrew P., additional, Antohi, Laura E., additional, Ben Gal, Tuvia, additional, Farmakis, Dimitrios, additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Lopatin, Yuri, additional, Tramonte, Francesco, additional, Lyon, Alexander, additional, Masip, Josep, additional, Miro, Oscar, additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Radu, Razvan I., additional, Abdelhamid, Magdy, additional, Anker, Stefan, additional, and Chioncel, Ovidiu, additional
- Published
- 2022
- Full Text
- View/download PDF
21. Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology
- Author
-
Núñez, Julio, primary, de la Espriella, Rafael, additional, Rossignol, Patrick, additional, Voors, Adriaan A., additional, Mullens, Wilfried, additional, Metra, Marco, additional, Chioncel, Ovidiu, additional, Januzzi, James L., additional, Mueller, Christian, additional, Richards, A. Mark, additional, de Boer, Rudolf A., additional, Thum, Thomas, additional, Arfsten, Henrike, additional, González, Arantxa, additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Gal, Tuvia Ben, additional, Biegus, Jan, additional, Cohen‐Solal, Alain, additional, Böhm, Michael, additional, Emdin, Michele, additional, Jankowska, Ewa A., additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Jhund, Pardeep S., additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Milicic, Davor, additional, Moura, Brenda, additional, Piepoli, Massimo F., additional, Ponikowski, Piotr, additional, Rakisheva, Amina, additional, Ristic, Arsen, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo G., additional, Van Linthout, Sophie, additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Coats, Andrew J.S., additional, and Bayes‐Genis, Antoni, additional
- Published
- 2022
- Full Text
- View/download PDF
22. Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas
- Author
-
Palazzuoli, Alberto, Metra, Marco, Collins, Sean P., Adamo, Marianna, Ambrosy, Andrew P., Antohi, Laura E., Ben Gal, Tuvia, Farmakis, Dimitrios, Gustafsson, Finn, Hill, Loreena, Lopatin, Yuri, Tramonte, Francesco, Lyon, Alexander, Masip, Josep, Miro, Oscar, Moura, Brenda, MULLENS, Wilfried, Radu, Razvan, I, Abdelhamid, Magdy, Anker, Stefan, Chioncel, Ovidiu, Gustafsson, Finn/0000-0003-2144-341X, Palazzuoli, Alberto, Metra, Marco, Collins, Sean P., Adamo, Marianna, Ambrosy, Andrew P., Antohi, Laura E., Ben Gal, Tuvia, Farmakis, Dimitrios, Gustafsson, Finn, Hill, Loreena, Lopatin, Yuri, Tramonte, Francesco, Lyon, Alexander, Masip, Josep, Miro, Oscar, Moura, Brenda, MULLENS, Wilfried, Radu, Razvan, I, Abdelhamid, Magdy, Anker, Stefan, and Chioncel, Ovidiu
- Subjects
Diagnostic differentiation ,COVID-19 ,Heart failure ,Management - Abstract
The coronavirus 2019 (COVID-19) infection pandemic has affected the care of patients with heart failure (HF). Several consensus documents describe the appropriate diagnostic algorithm and treatment approach for patients with HF and associated COVID-19 infection. However, few questions about the mechanisms by which COVID can exacerbate HF in patients with high-risk (Stage B) or symptomatic HF (Stage C) remain unanswered. Therefore, the type of HF occurring during infection is poorly investigated. The diagnostic differentiation and management should be focused on the identification of the HF phenotype, underlying causes, and subsequent tailored therapy. In this framework, the relationship existing between COVID and onset of acute decompensated HF, isolated right HF, and cardiogenic shock is questioned, and the specific management is mainly based on local hospital organization rather than a standardized model. Similarly, some specific populations such as advanced HF, heart transplant, patients with left ventricular assist device (LVAD), or valve disease remain under investigated. In this systematic review, we examine recent advances regarding the relationships between HF and COVID-19 pandemic with respect to epidemiology, pathogenetic mechanisms, and differential diagnosis. Also, according to the recent HF guidelines definition, we highlight different clinical profile identification, pointing out the main concerns in understudied HF populations.
- Published
- 2022
23. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.
- Author
-
Pieske, Burkert, Pieske‐Kraigher, Elisabeth, Lam, Carolyn S.P., Melenovský, Vojtěch, Sliwa, Karen, Lopatin, Yuri, Arango, Juan Luis, Bahit, M. Cecilia, O'Connor, Christopher M., Patel, Mahesh J., Roessig, Lothar, Morris, Daniel A., Kropf, Martin, Westerhout, Cynthia M., Zheng, Yinggan, and Armstrong, Paul W.
- Subjects
HEART failure patients ,VENTRICULAR ejection fraction ,ECHOCARDIOGRAPHY ,HEART failure ,CARDIOVASCULAR disease related mortality - Abstract
Aim: Vericiguat significantly reduced the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death in the VICTORIA trial. It is unknown if these outcome benefits are related to reverse left ventricular (LV) remodelling with vericiguat in patients with HF with reduced ejection fraction (HFrEF). The aim of this study was to compare the effects of vericiguat versus placebo on LV structure and function after 8 months of therapy in patients with HFrEF. Methods and results: Standardized transthoracic echocardiography (TTE) was performed at baseline and after 8 months of therapy in a subset of HFrEF patients in VICTORIA. The co‐primary endpoints were changes in LV end‐systolic volume index (LVESVI) and LV ejection fraction (LVEF). Quality assurance and central reading were performed by an echocardiographic core laboratory blinded to treatment assignment. A total of 419 patients (208 vericiguat, 211 placebo) with high‐quality paired TTE at baseline and 8 months were included. Baseline clinical characteristics were well balanced between treatment groups and echocardiographic characteristics were representative of patients with HFrEF. LVESVI significantly declined (60.7 ± 26.8 to 56.8 ± 30.4 ml/m2; p < 0.01) and LVEF significantly increased (33.0 ± 9.4% to 36.1 ± 10.2%; p < 0.01) in the vericiguat group, but similarly in the placebo group (absolute changes for vericiguat vs. placebo: LVESVI −3.8 ± 15.4 vs. −7.1 ± 20.5 ml/m2; p = 0.07 and LVEF +3.2 ± 8.0% vs. +2.4 ± 7.6%; p = 0.31). The absolute rate per 100 patient‐years of the primary composite endpoint at 8 months tended to be lower in the vericiguat group (19.8) than the placebo group (29.6) (p = 0.07). Conclusions: In this pre‐specified echocardiographic study, significant improvements in LV structure and function occurred over 8 months in both vericiguat and placebo in a high‐risk HFrEF population with recent worsening HF. Further studies are warranted to define the mechanisms of vericiguat's benefit in HFrEF. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Impact analysis of heart failure across European countries: an ESC‐HFA position paper
- Author
-
Rosano, Giuseppe M.C., primary, Seferovic, Petar, additional, Savarese, Gianluigi, additional, Spoletini, Ilaria, additional, Lopatin, Yuri, additional, Gustafsson, Fin, additional, Bayes‐Genis, Antoni, additional, Jaarsma, Tiny, additional, Abdelhamid, Magdy, additional, Miqueo, Arantxa Gonzalez, additional, Piepoli, Massimo, additional, Tocchetti, Carlo G., additional, Ristić, Arsen D., additional, Jankowska, Ewa, additional, Moura, Brenda, additional, Hill, Loreena, additional, Filippatos, Gerasimos, additional, Metra, Marco, additional, Milicic, Davor, additional, Thum, Thomas, additional, Chioncel, Ovidiu, additional, Ben Gal, Tuvia, additional, Lund, Lars H., additional, Farmakis, Dimitrios, additional, Mullens, Wilfried, additional, Adamopoulos, Stamatis, additional, Bohm, Michael, additional, Norhammar, Anna, additional, Bollmann, Andreas, additional, Banerjee, Amitava, additional, Maggioni, Aldo P., additional, Voors, Adriaan, additional, Solal, Alain Cohen, additional, and Coats, Andrew J.S., additional
- Published
- 2022
- Full Text
- View/download PDF
25. Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology
- Author
-
Seferović, Peter, primary, Farmakis, Dimitrios, additional, Bayes‐Genis, Antoni, additional, Ben Gal, Tuvia, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Ferrari, Roberto, additional, Filippatos, Gerasimos, additional, Hill, Loreena, additional, Jankowska, Ewa, additional, Lainscak, Mitja, additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Mebazaa, Alexandre, additional, Metra, Marco, additional, Moura, Brenda, additional, Rosano, Giuseppe, additional, Thum, Thomas, additional, Voors, Adriaan, additional, and Coats, Andrew J.S., additional
- Published
- 2022
- Full Text
- View/download PDF
26. Cardiac Remodelling Part 1: From Cells and Tissues to Circulating Biomarkers:From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
- Author
-
González, Arantxa, Richards, A Mark, Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao‐Pires, Inês, Díez, Javier, Foo, Roger SY, Chan, Mark Yan Yee, Aimo, Alberto, Anene‐Nzelu, George C, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Belenkov, Yuri, Gal, Tuvia B, Cohen‐Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep S, Lopatin, Yuri, Lund, Lars H, Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristic, Arsen, Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G, Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew JS, and Bayes‐Genis, Antoni
- Subjects
Tissue ,Cells ,Cardiology and Cardiovascular Medicine ,Biomarkers ,Remodeling - Abstract
Cardiac remodelling refers to changes in left ventricular (LV) structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leukocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g., proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and many biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of review paper on biomarkers of cardiac remodelling.
- Published
- 2022
27. Impact analysis of heart failure across European countries : an ESC-HFA position paper
- Author
-
Rosano, Giuseppe M. C., Seferovic, Petar, Savarese, Gianluigi, Spoletini, Ilaria, Lopatin, Yuri, Gustafsson, Fin, Bayes-Genis, Antoni, Jaarsma, Tiny, Abdelhamid, Magdy, Miqueo, Arantxa Gonzalez, Piepoli, Massimo, Tocchetti, Carlo G., Ristic, Arsen D., Jankowska, Ewa, Moura, Brenda, Hill, Loreena, Filippatos, Gerasimos, Metra, Marco, Milicic, Davor, Thum, Thomas, Chioncel, Ovidiu, Ben Gal, Tuvia, Lund, Lars H., Farmakis, Dimitrios, Mullens, Wilfried, Adamopoulos, Stamatis, Bohm, Michael, Norhammar, Anna, Bollmann, Andreas, Banerjee, Amitava, Maggioni, Aldo P., Voors, Adriaan, Solal, Alain Cohen, Coats, Andrew J. S., Rosano, Giuseppe M. C., Seferovic, Petar, Savarese, Gianluigi, Spoletini, Ilaria, Lopatin, Yuri, Gustafsson, Fin, Bayes-Genis, Antoni, Jaarsma, Tiny, Abdelhamid, Magdy, Miqueo, Arantxa Gonzalez, Piepoli, Massimo, Tocchetti, Carlo G., Ristic, Arsen D., Jankowska, Ewa, Moura, Brenda, Hill, Loreena, Filippatos, Gerasimos, Metra, Marco, Milicic, Davor, Thum, Thomas, Chioncel, Ovidiu, Ben Gal, Tuvia, Lund, Lars H., Farmakis, Dimitrios, Mullens, Wilfried, Adamopoulos, Stamatis, Bohm, Michael, Norhammar, Anna, Bollmann, Andreas, Banerjee, Amitava, Maggioni, Aldo P., Voors, Adriaan, Solal, Alain Cohen, and Coats, Andrew J. S.
- Abstract
Heart failure (HF) is a long-term clinical syndrome, with increasing prevalence and considerable healthcare costs that are further expected to increase dramatically. Despite significant advances in therapy and prevention, mortality and morbidity remain high and quality of life poor. Epidemiological data, that is, prevalence, incidence, mortality, and morbidity, show geographical variations across the European countries, depending on differences in aetiology, clinical characteristics, and treatment. However, data on the prevalence of the disease are scarce, as are those on quality of life. For these reasons, the ESC-HFA has developed a position paper to comprehensively assess our understanding of the burden of HF in Europe, in order to guide future policies for this syndrome. This manuscript will discuss the available epidemiological data on HF prevalence, outcomes, and human costs-in terms of quality of life-in European countries.
- Published
- 2022
- Full Text
- View/download PDF
28. Impact analysis of heart failure across European countries:an ESC-HFA position paper
- Author
-
Rosano, Giuseppe M. C., Seferovic, Petar, Savarese, Gianluigi, Spoletini, Ilaria, Lopatin, Yuri, Gustafsson, Fin, Bayes-Genis, Antoni, Jaarsma, Tiny, Abdelhamid, Magdy, Miqueo, Arantxa Gonzalez, Piepoli, Massimo, Tocchetti, Carlo G., Ristić, Arsen D., Jankowska, Ewa, Moura, Brenda, Hill, Loreena, Filippatos, Gerasimos, Metra, Marco, Milicic, Davor, Thum, Thomas, Chioncel, Ovidiu, Ben Gal, Tuvia, Lund, Lars H., Farmakis, Dimitrios, Mullens, Wilfried, Adamopoulos, Stamatis, Bohm, Michael, Norhammar, Anna, Bollmann, Andreas, Banerjee, Amitava, Maggioni, Aldo P., Voors, Adriaan, Solal, Alain Cohen, Coats, Andrew J. S., Rosano, Giuseppe M. C., Seferovic, Petar, Savarese, Gianluigi, Spoletini, Ilaria, Lopatin, Yuri, Gustafsson, Fin, Bayes-Genis, Antoni, Jaarsma, Tiny, Abdelhamid, Magdy, Miqueo, Arantxa Gonzalez, Piepoli, Massimo, Tocchetti, Carlo G., Ristić, Arsen D., Jankowska, Ewa, Moura, Brenda, Hill, Loreena, Filippatos, Gerasimos, Metra, Marco, Milicic, Davor, Thum, Thomas, Chioncel, Ovidiu, Ben Gal, Tuvia, Lund, Lars H., Farmakis, Dimitrios, Mullens, Wilfried, Adamopoulos, Stamatis, Bohm, Michael, Norhammar, Anna, Bollmann, Andreas, Banerjee, Amitava, Maggioni, Aldo P., Voors, Adriaan, Solal, Alain Cohen, and Coats, Andrew J. S.
- Abstract
Heart failure (HF) is a long-term clinical syndrome, with increasing prevalence and considerable healthcare costs that are further expected to increase dramatically. Despite significant advances in therapy and prevention, mortality and morbidity remain high and quality of life poor. Epidemiological data, that is, prevalence, incidence, mortality, and morbidity, show geographical variations across the European countries, depending on differences in aetiology, clinical characteristics, and treatment. However, data on the prevalence of the disease are scarce, as are those on quality of life. For these reasons, the ESC-HFA has developed a position paper to comprehensively assess our understanding of the burden of HF in Europe, in order to guide future policies for this syndrome. This manuscript will discuss the available epidemiological data on HF prevalence, outcomes, and human costs—in terms of quality of life—in European countries.
- Published
- 2022
29. Congestion in heart failure:a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology
- Author
-
Núñez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A, Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L, Mueller, Christian, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, González, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Ben Gal, Tuvia, Biegus, Jan, Cohen-Solal, Alain, Böhm, Michael, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S, Lopatin, Yuri, Lund, Lars H., Milicic, Davor, Moura, Brenda, Piepoli, Massimo F, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Bayes-Genis, Antoni, Núñez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A, Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L, Mueller, Christian, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, González, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Ben Gal, Tuvia, Biegus, Jan, Cohen-Solal, Alain, Böhm, Michael, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S, Lopatin, Yuri, Lund, Lars H., Milicic, Davor, Moura, Brenda, Piepoli, Massimo F, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., and Bayes-Genis, Antoni
- Abstract
Congestion is a cardinal sign of heart failure (HF). In the past, it was seen as a homogeneous epiphenomenon that identified patients with advanced HF. However, current evidence shows that congestion in HF varies in quantity and distribution. This updated view advocates for a congestive-driven classification of HF according to onset (acute vs. chronic), regional distribution (systemic vs. pulmonary), compartment of distribution (intravascular vs. extravascular), and clinical vs. subclinical. Thus, this review will focus on the utility of circulating biomarkers for assessing and managing the different fluid overload phenotypes. This discussion focused on the clinical utility of the natriuretic peptides, carbohydrate antigen 125 (also called mucin 16), bio-adrenomedullin and mid-regional pro-adrenomedullin, ST2 (also known as interleukin-1 receptor-like 1), cluster of differentiation 146, troponin, C-terminal pro-endothelin-1, and parameters of haemoconcentration. The utility of circulation biomarkers on top of clinical evaluation, haemodynamics, and imaging needs to be better determined by dedicated studies. Some multiparametric frameworks in which these tools contribute to management are proposed.
- Published
- 2022
30. Preventing heart failure:a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
- Author
-
Piepoli, Massimo F, Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B., Biegus, Jan, Böehm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, Maria G, de Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S P, Løchen, Maja-Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M., Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W M Monique, Volterrani, Maurizio, Von Heahling, Stephan, Hoes, Arno, Piepoli, Massimo F, Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B., Biegus, Jan, Böehm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, Maria G, de Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S P, Løchen, Maja-Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M., Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W M Monique, Volterrani, Maurizio, Von Heahling, Stephan, and Hoes, Arno
- Abstract
The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present position paper aims to provide practical evidence-based information to support the implementation of effective preventive measures. After reviewing the most common risk factors, an overview of the population attributable risks in different continents is presented, to identify potentially effective opportunities for prevention and to inform preventive strategies. Finally, potential interventions that have been proposed and have been shown to be effective in preventing heart failure are listed.
- Published
- 2022
31. Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings:A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
- Author
-
Aimo, Alberto, Vergaro, Giuseppe, González, Arantxa, Barison, Andrea, Lupón, Josep, Delgado, Victoria, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao-Pires, Inês, Díez, Javier, Foo, Roger S. Y., Chan, Mark Yan Yee, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Belenkov, Yuri, Ben Gal, Tuvia, Cohen-Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristić, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Emdin, Michele, Bayes-Genis, Antoni, Aimo, Alberto, Vergaro, Giuseppe, González, Arantxa, Barison, Andrea, Lupón, Josep, Delgado, Victoria, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao-Pires, Inês, Díez, Javier, Foo, Roger S. Y., Chan, Mark Yan Yee, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Belenkov, Yuri, Ben Gal, Tuvia, Cohen-Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristić, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Emdin, Michele, and Bayes-Genis, Antoni
- Abstract
In patients with heart failure, the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with heart failure with reduced ejection fraction because most studies on cardiac remodelling focused on this setting.
- Published
- 2022
32. Heart failure during the COVID-19 pandemic:clinical, diagnostic, management, and organizational dilemmas
- Author
-
Palazzuoli, Alberto, Metra, Marco, Collins, Sean P., Adamo, Marianna, Ambrosy, Andrew P., Antohi, Laura E., Ben Gal, Tuvia, Farmakis, Dimitrios, Gustafsson, Finn, Hill, Loreena, Lopatin, Yuri, Tramonte, Francesco, Lyon, Alexander, Masip, Josep, Miro, Oscar, Moura, Brenda, Mullens, Wilfried, Radu, Razvan I., Abdelhamid, Magdy, Anker, Stefan, Chioncel, Ovidiu, Palazzuoli, Alberto, Metra, Marco, Collins, Sean P., Adamo, Marianna, Ambrosy, Andrew P., Antohi, Laura E., Ben Gal, Tuvia, Farmakis, Dimitrios, Gustafsson, Finn, Hill, Loreena, Lopatin, Yuri, Tramonte, Francesco, Lyon, Alexander, Masip, Josep, Miro, Oscar, Moura, Brenda, Mullens, Wilfried, Radu, Razvan I., Abdelhamid, Magdy, Anker, Stefan, and Chioncel, Ovidiu
- Abstract
The coronavirus 2019 (COVID-19) infection pandemic has affected the care of patients with heart failure (HF). Several consensus documents describe the appropriate diagnostic algorithm and treatment approach for patients with HF and associated COVID-19 infection. However, few questions about the mechanisms by which COVID can exacerbate HF in patients with high-risk (Stage B) or symptomatic HF (Stage C) remain unanswered. Therefore, the type of HF occurring during infection is poorly investigated. The diagnostic differentiation and management should be focused on the identification of the HF phenotype, underlying causes, and subsequent tailored therapy. In this framework, the relationship existing between COVID and onset of acute decompensated HF, isolated right HF, and cardiogenic shock is questioned, and the specific management is mainly based on local hospital organization rather than a standardized model. Similarly, some specific populations such as advanced HF, heart transplant, patients with left ventricular assist device (LVAD), or valve disease remain under investigated. In this systematic review, we examine recent advances regarding the relationships between HF and COVID-19 pandemic with respect to epidemiology, pathogenetic mechanisms, and differential diagnosis. Also, according to the recent HF guidelines definition, we highlight different clinical profile identification, pointing out the main concerns in understudied HF populations.
- Published
- 2022
33. Preventing heart failure:A position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
- Author
-
Piepoli, Massimo F., Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B., Biegus, Jan, Böhm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, Maria G., De Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S.P., Løchen, Maja Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M., Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W. M., Volterrani, Maurizio, Von Haehling, Stephan, Hoes, Arno, Piepoli, Massimo F., Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B., Biegus, Jan, Böhm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, Maria G., De Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S.P., Løchen, Maja Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M., Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W. M., Volterrani, Maurizio, Von Haehling, Stephan, and Hoes, Arno
- Abstract
The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present consensus document aims to provide practical evidence-based information to support the implementation of effective preventive measures. After reviewing the most common risk factors, an overview of the population attributable risks in different continents is presented, to identify potentially effective opportunities for prevention and to inform preventive strategies. Finally, potential interventions that have been proposed and have been shown to be effective in preventing HF are listed.
- Published
- 2022
34. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology
- Author
-
Nunez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A., Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L., Mueller, Christian, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Gonzalez, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Gal, Tuvia Ben, Biegus, Jan, Cohen-Solal, Alain, Boehm, Michael, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Milicic, Davor, Moura, Brenda, Piepoli, Massimo F., Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Bayes-Genis, Antoni, Nunez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A., Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L., Mueller, Christian, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Gonzalez, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Gal, Tuvia Ben, Biegus, Jan, Cohen-Solal, Alain, Boehm, Michael, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Milicic, Davor, Moura, Brenda, Piepoli, Massimo F., Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., and Bayes-Genis, Antoni
- Abstract
Congestion is a cardinal sign of heart failure (HF). In the past, it was seen as a homogeneous epiphenomenon that identified patients with advanced HF. However, current evidence shows that congestion in HF varies in quantity and distribution. This updated view advocates for a congestive-driven classification of HF according to onset (acute vs. chronic), regional distribution (systemic vs. pulmonary), compartment of distribution (intravascular vs. extravascular), and clinical vs. subclinical. Thus, this review will focus on the utility of circulating biomarkers for assessing and managing the different fluid overload phenotypes. This discussion focused on the clinical utility of the natriuretic peptides, carbohydrate antigen 125 (also called mucin 16), bio-adrenomedullin and mid-regional pro-adrenomedullin, ST2 (also known as interleukin-1 receptor-like 1), cluster of differentiation 146, troponin, C-terminal pro-endothelin-1, and parameters of haemoconcentration. The utility of circulation biomarkers on top of clinical evaluation, haemodynamics, and imaging needs to be better determined by dedicated studies. Some multiparametric frameworks in which these tools contribute to management are proposed., Funding Agencies|Ministry of Economy and Competitiveness; Instituto Carlos III [PI20/00392]; CIBER Cardiovascular [16/11/00420, 16/11/00403]
- Published
- 2022
- Full Text
- View/download PDF
35. Cardiac remodelling – Part 1:From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
- Author
-
González, Arantxa, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao-Pires, Inês, Díez, Javier, Foo, Roger S.Y., Chan, Mark Y., Aimo, Alberto, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristić, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J.S., Bayés-Genís, Antoni, González, Arantxa, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao-Pires, Inês, Díez, Javier, Foo, Roger S.Y., Chan, Mark Y., Aimo, Alberto, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristić, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J.S., and Bayés-Genís, Antoni
- Abstract
Cardiac remodelling refers to changes in left ventricular structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery (reverse remodelling) in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leucocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g. proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and several biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of this review paper on biomarkers of cardiac remodelling.
- Published
- 2022
36. Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
- Author
-
Gonzalez, Arantxa, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Y., Aimo, Alberto, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Boehm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Bayes-Genis, Antoni, Gonzalez, Arantxa, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Y., Aimo, Alberto, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Boehm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., and Bayes-Genis, Antoni
- Abstract
Cardiac remodelling refers to changes in left ventricular structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery (reverse remodelling) in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leucocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g. proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and several biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of this review paper on biomarkers of cardiac remodelling., Funding Agencies|Spanish Ministry of Science, Innovation and Universities Institute of Health Carlos III (ISCIII) [PI18/01469, PI21/00946, CB16/11/00403, CB16/11/00483]; European Regional Development FundsEuropean Commission; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [2019-848109-2]; European Research CouncilEuropean Research Council (ERC)European Commission [ERC CoG 818715]; ERC-PoC Megfib; National Medical Research Council of Singapore (NMRC)National Medical Research Council, Singapore [NMRC/STaR/0022/2014, MOH-000280]; Health Research Council of New ZealandHealth Research Council of New Zealand [02/152, 08/070, 11/1070]; National Heart Foundation of New Zealand; New Zealand Lotteries Grant Board; Foundation for Research, Science and TechnologyNew Zealand Foundation for Research, Science and Technology; Christchurch Heart Institute Trust; Netherlands Heart FoundationNetherlands Heart Foundation [2017-21, 2017-11, 2018-30, 2020B005]; leDucq FoundationLeducq Foundation; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [KFO311, TRR267, TTR 219, TRR 1470]; Karolinska Institutet, the Swedish Research CouncilSwedish Research Council [523-2014-2336]; Swedish Heart Lung FoundationSwedish Heart-Lung Foundation [20150557, 20190310]; Stockholm County CouncilStockholm County Council [20170112, 20190525]
- Published
- 2022
- Full Text
- View/download PDF
37. Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
- Author
-
Aimo, Alberto, Vergaro, Giuseppe, Gonzalez, Arantxa, Barison, Andrea, Lupon, Josep, Delgado, Victoria, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Yan Yee, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Bohm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Emdin, Michele, Bayes-Genis, Antoni, Aimo, Alberto, Vergaro, Giuseppe, Gonzalez, Arantxa, Barison, Andrea, Lupon, Josep, Delgado, Victoria, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Yan Yee, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Bohm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Emdin, Michele, and Bayes-Genis, Antoni
- Abstract
In patients with heart failure, the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with heart failure with reduced ejection fraction because most studies on cardiac remodelling focused on this setting.
- Published
- 2022
- Full Text
- View/download PDF
38. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
- Author
-
Piepoli, Massimo Francesco, Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B., Biegus, Jan, Böhm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, María Generosa, de Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S.P., Løchen, Maja-Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M., Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W.M., Volterrani, Maurizio, Von Haehling, Stephan, Hoes, Arno, Piepoli, Massimo Francesco, Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B., Biegus, Jan, Böhm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, María Generosa, de Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S.P., Løchen, Maja-Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M., Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W.M., Volterrani, Maurizio, Von Haehling, Stephan, and Hoes, Arno
- Abstract
[Abstract] The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present consensus document aims to provide practical evidence-based information to support the implementation of effective preventive measures. After reviewing the most common risk factors, an overview of the population attributable risks in different continents is presented, to identify potentially effective opportunities for prevention and to inform preventive strategies. Finally, potential interventions that have been proposed and have been shown to be effective in preventing HF are listed.
- Published
- 2022
39. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
- Author
-
Piepoli, Massimo F., Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B., Biegus, Jan, Bohm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, Maria G., de Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S. P., Lochen, Maja-Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M., Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W. M., Volterrani, Maurizio, Von Haehling, Stephan, Hoes, Arno, Piepoli, Massimo F., Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B., Biegus, Jan, Bohm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, Maria G., de Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S. P., Lochen, Maja-Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M., Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W. M., Volterrani, Maurizio, Von Haehling, Stephan, and Hoes, Arno
- Abstract
The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present consensus document aims to provide practical evidence-based information to support the implementation of effective preventive measures. After reviewing the most common risk factors, an overview of the population attributable risks in different continents is presented, to identify potentially effective opportunities for prevention and to inform preventive strategies. Finally, potential interventions that have been proposed and have been shown to be effective in preventing HF are listed.
- Published
- 2022
- Full Text
- View/download PDF
40. Impact analysis of heart failure across European countries: an ESC-HFA position paper
- Author
-
Verplegingswetenschap, Circulatory Health, Rosano, Giuseppe M C, Seferovic, Petar, Savarese, Gianluigi, Spoletini, Ilaria, Lopatin, Yuri, Gustafsson, Fin, Bayes-Genis, Antoni, Jaarsma, Tiny, Abdelhamid, Magdy, Miqueo, Arantxa Gonzalez, Piepoli, Massimo, Tocchetti, Carlo G, Ristić, Arsen D, Jankowska, Ewa, Moura, Brenda, Hill, Loreena, Filippatos, Gerasimos, Metra, Marco, Milicic, Davor, Thum, Thomas, Chioncel, Ovidiu, Ben Gal, Tuvia, Lund, Lars H, Farmakis, Dimitrios, Mullens, Wilfried, Adamopoulos, Stamatis, Bohm, Michael, Norhammar, Anna, Bollmann, Andreas, Banerjee, Amitava, Maggioni, Aldo P, Voors, Adriaan, Solal, Alain Cohen, Coats, Andrew J S, Verplegingswetenschap, Circulatory Health, Rosano, Giuseppe M C, Seferovic, Petar, Savarese, Gianluigi, Spoletini, Ilaria, Lopatin, Yuri, Gustafsson, Fin, Bayes-Genis, Antoni, Jaarsma, Tiny, Abdelhamid, Magdy, Miqueo, Arantxa Gonzalez, Piepoli, Massimo, Tocchetti, Carlo G, Ristić, Arsen D, Jankowska, Ewa, Moura, Brenda, Hill, Loreena, Filippatos, Gerasimos, Metra, Marco, Milicic, Davor, Thum, Thomas, Chioncel, Ovidiu, Ben Gal, Tuvia, Lund, Lars H, Farmakis, Dimitrios, Mullens, Wilfried, Adamopoulos, Stamatis, Bohm, Michael, Norhammar, Anna, Bollmann, Andreas, Banerjee, Amitava, Maggioni, Aldo P, Voors, Adriaan, Solal, Alain Cohen, and Coats, Andrew J S
- Published
- 2022
41. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
- Author
-
Verplegingswetenschap, Circulatory Health, Cardiovasculaire Epi Team 7B, Onderzoek Precision medicine, Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Planetary Health & Exposoom, Cancer, Directie Raad van Bestuur, Piepoli, Massimo F, Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B, Biegus, Jan, Böhm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, Maria G, de Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S P, Løchen, Maja-Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M, Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W M, Volterrani, Maurizio, Von Haehling, Stephan, Hoes, Arno, Verplegingswetenschap, Circulatory Health, Cardiovasculaire Epi Team 7B, Onderzoek Precision medicine, Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Planetary Health & Exposoom, Cancer, Directie Raad van Bestuur, Piepoli, Massimo F, Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B, Biegus, Jan, Böhm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, Maria G, de Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S P, Løchen, Maja-Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M, Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W M, Volterrani, Maurizio, Von Haehling, Stephan, and Hoes, Arno
- Published
- 2022
42. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
- Author
-
Aimo, Alberto, primary, Vergaro, Giuseppe, additional, González, Arantxa, additional, Barison, Andrea, additional, Lupón, Josep, additional, Delgado, Victoria, additional, Richards, A Mark, additional, de Boer, Rudolf A., additional, Thum, Thomas, additional, Arfsten, Henrike, additional, Hülsmann, Martin, additional, Falcao‐Pires, Inês, additional, Díez, Javier, additional, Foo, Roger S.Y., additional, Chan, Mark Yan Yee, additional, Anene‐Nzelu, Chukwuemeka G., additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Belenkov, Yuri, additional, Ben Gal, Tuvia, additional, Cohen‐Solal, Alain, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Jankowska, Ewa A., additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Januzzi, James L., additional, Jhund, Pardeep, additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Metra, Marco, additional, Milicic, Davor, additional, Moura, Brenda, additional, Mueller, Christian, additional, Mullens, Wilfried, additional, Núñez, Julio, additional, Piepoli, Massimo F., additional, Rakisheva, Amina, additional, Ristić, Arsen D., additional, Rossignol, Patrick, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo G., additional, van Linthout, Sophie, additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Coats, Andrew J.S., additional, Emdin, Michele, additional, and Bayes‐Genis, Antoni, additional
- Published
- 2022
- Full Text
- View/download PDF
43. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
- Author
-
González, Arantxa, primary, Richards, A. Mark, additional, de Boer, Rudolf A., additional, Thum, Thomas, additional, Arfsten, Henrike, additional, Hülsmann, Martin, additional, Falcao‐Pires, Inês, additional, Díez, Javier, additional, Foo, Roger S.Y., additional, Chan, Mark Y., additional, Aimo, Alberto, additional, Anene‐Nzelu, Chukwuemeka G., additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Belenkov, Yuri, additional, Ben Gal, Tuvia, additional, Cohen‐Solal, Alain, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Delgado, Victoria, additional, Emdin, Michele, additional, Jankowska, Ewa A., additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Januzzi, James L., additional, Jhund, Pardeep S., additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Metra, Marco, additional, Milicic, Davor, additional, Moura, Brenda, additional, Mueller, Christian, additional, Mullens, Wilfried, additional, Núñez, Julio, additional, Piepoli, Massimo F., additional, Rakisheva, Amina, additional, Ristić, Arsen D., additional, Rossignol, Patrick, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo G., additional, Van Linthout, Sophie, additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Coats, Andrew J.S., additional, and Bayés‐Genís, Antoni, additional
- Published
- 2022
- Full Text
- View/download PDF
44. Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme
- Author
-
Seferovic, Petar M., Piepoli, Massimo F., Lopatin, Yuri, Jankowska, Ewa, Polovina, Marija, Anguita-Sanchez, Manuel, Stoerk, Stefan, Lainscak, Mitja, Milicic, Davor, Milinkovic, Ivan, Filippatos, Gerasimos, Coats, Andrew J. S., Anker, Stefan, Backs, Johannes, Bauersachs, Johann, Ben Gal, Tuvia, de Boer, Rudolf A., Doehner, Wolfram, Celutkiene, Jelena, Chioncel, Ovidiu, Heymans, Stephane, Hill, Loreena, Jaarsma, Tiny, Lund, Lars H., Lyon, Alexander R., Metra, Marco, Moura, Brenda, Mueller, Cristian, Mullens, Wilfried, Ponikowski, Piotr, Rosano, Giuseppe, Ruschitzka, Frank, Thum, Thomas, Volterrani, Maurizio, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - H02 Cardiomyopathy, and Cardiovascular Centre (CVC)
- Subjects
medicine.medical_specialty ,Cardiology ,Heart failure ,Audit ,ORGANIZATION ,030204 cardiovascular system & hematology ,Accreditation ,DISEASE MANAGEMENT PROGRAMS ,03 medical and health sciences ,0302 clinical medicine ,Multidisciplinary approach ,Internal medicine ,Intensive care ,Health care ,Disease management ,Medicine ,Humans ,Disease management (health) ,Human resources ,Quality of Health Care ,Heart Failure ,Patient ,business.industry ,Research ,Multidisciplinary care ,Quality of care ,ADMISSION ,3. Good health ,CLINICS ,Europe ,SURVIVAL ,Cardiology and Cardiovascular Medicine ,business ,Hospital accreditation ,Editorial Comment ,INTERVENTION ,MULTIDISCIPLINARY - Abstract
Heart failure (HF) is the major contributor to cardiovascular morbidity and mortality. Given its rising prevalence, the costs of HF care can be expected to increase. Multidisciplinary management of HF can improve quality of care and survival. However, specialized HF programmes are not widely available in most European countries. These circumstances underlie the suggestion of the Heart Failure Association (HFA)of the European Society of Cardiology (ESC) for the development of quality of care centres (QCCs). These are defined as health care institutions that provide multidisciplinary HF management at all levels of care (primary, secondary and tertiary), are accredited by the HFA/ESC and are implemented into existing health care systems. Their major goals are to unify and improve the quality of HF care, and to promote collaboration in education and research activities. Three types of QCC are suggested: community QCCs (primary care facilities able to provide non-invasive assessment and optimal therapy); specialized QCCs (district hospitals with intensive care units, able to provide cardiac catheterization and device implantation services), and advanced QCCs (national reference centres able to deliver advanced and innovative HF care and research). QCC accreditation will require compliance with general and specific HFA/ESC accreditation standards. General requirements include confirmation of the centre's existence, commitment to QCC implementation, and collaboration with other QCCs. Specific requirements include validation of the centre's level of care, service portfolio, facilities and equipment, management, human resources, process measures, quality indicators and outcome measures. Audit and recertification at 4-6-year intervals are also required. The implementation of QCCs will evolve gradually, following a pilot phase in selected countries. The present document summarizes the definition, major goals, development, classification and crucial aspects of the accreditation process of the HFA/ESC QCC Programme.
- Published
- 2020
45. Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology
- Author
-
Mullens, Wilfried, Coats, Andrew J.S., Seferović, Petar M., Metra, Marco I., Mebazaa, Alexandre, Ruschitzka, Frank T., Filippatos, Gerasimos S., Volterrani, Maurizio, Ponikowski, Piotr P., Jankowska, Ewa Anita, Chioncel, Ovidiu, McDonagh, Theresa A., Piepoli, Massimo F., Milicic, Davor, Thum, Thomas, Hill, Loreena Michelle, Abdelhamid, Magdy, Adamopoulos, Stamatis, Belenkov, Yuri, Ben-Gal, Tuvia, Böhm, Michael, Cohen-Solal, Alain, Gustafsson, Finn, Jaarsma, Tiny, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen D., Bayes-Genis, Antonio, Van Linthout, Sophia, Anker, Stefan D., Tocchetti, Carlo Gabriele, Lopatin, Yuri, Lund, Lars, Savarese, Gianluigi, Čelutkienė, Jelena, Cowie, Martin, Lambrinou, Ekaterini, Ray, Robin, Lainscak, Mitja, Skouri, Hadi, Wallner, Markus, Rosano, Giuseppe M C, Mullens, Wilfried, Coats, Andrew, Seferovic, Petar, Metra, Marco, Mebazaa, Alexandre, Ruschitzka, Frank, Filippatos, Gerasimo, Volterrani, Maurizio, Ponikowski, Piotr, Jankowska, Ewa A, Chioncel, Ovidiu, Mcdonagh, Theresa A, Piepoli, Massimo F, Milicic, Davor, Thum, Thoma, Hill, Loreena, Abdelhamid, Magdy, Adamopoulos, Stamati, Belenkov, Yuri, Gal, Tuvia Ben, Böhm, Michael, Cohen-Solal, Alain, Gustafsson, Finn, Jaarsma, Tiny, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen, Bayes-Genis, Antonio, Van Linthout, Sophia, Anker, Stefan D, Tocchetti, Carlo Gabriele, Lopatin, Yury, Lund, Lar, Savarese, Gianluigi, Čelutkienė, Jelena, Cowie, Martin, Lambrinou, Ekaterini, Ray, Robin, Lainscak, Mitja, Skouri, Hadi, Wallner, Marku, and Rosano, Giuseppe M C
- Subjects
Heart Failure ,Certification ,Europe ,Humans ,Societies, Medical ,Cardiology ,Quality of patient-centred ,Heart failure ,Medical and Health Sciences ,Comprehensive educational programme ,Medical ,Quality of care centres ,Clinical Medicine ,Societies - Abstract
Heart failure (HF) is a devastating chronic and disabling disease with a wide variety of pharmaceutical and device treatment options which are becoming increasingly complex to implement. According to the Heart Failure Association (HFA) Atlas, a subspeciality resource aimed at sourcing contemporary data concerning the epidemiology and healthcare resources for HF, HF is prevalent in17.20 patients per1000 persons, accounting for 2671HFhospitalizations per million inhabitants annually in Europe.1HFpatients also suffer from a high prevalence of non-cardiac comorbidities, which adds complexity to their HF treatment and can negatively impact prognosis.2As a result, HF-related healthcare expenditure continues to rise, and healthcare organizations are becoming faced with the impossible challenge to provide the necessary financial and logistical support to this growing number of patients. In order to address these challenges, the HFA recently outlined the development of quality of care centres (QCC), in order to encourage multidisciplinary management of HF that will improve quality of care and survival.3However, there remains a significant unmet need to train sufficient multidisciplinary teams lead by HF specialists to take care of this expanding group of HF patients. In order to ensure that the next generation of medically-qualified HF specialists will receive high-quality training, this consensus statement of the HFA outlines the requirements for a European training and certification programme for such specialists. The primary goal of this comprehensive educational programme is to increase the quality of patient-centred care related to HF.
- Published
- 2022
46. Congestion in Heart Failure: a circulating biomarker-based perspective
- Author
-
Núñez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A, Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L, Mueller, Christian, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, González, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Gal, Tuvia Ben, Biegus, Jan, Cohen-Solal, Alain, Böhm, Michael, Emdin, Michele, Jankowska, Ewa A, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S, Lopatin, Yuri, Lund, Lars H, Milicic, Davor, Moura, Brenda, Piepoli, Massimo F, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G, Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew Js, and Bayes-Genis, Antoni
- Published
- 2022
47. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
- Author
-
Piepoli, Massimo F., primary, Adamo, Marianna, additional, Barison, Andrea, additional, Bestetti, Reinaldo B., additional, Biegus, Jan, additional, Böhm, Michael, additional, Butler, Javed, additional, Carapetis, Jonathan, additional, Ceconi, Claudio, additional, Chioncel, Ovidiu, additional, Coats, Andrew, additional, Crespo‐Leiro, Maria G., additional, de Simone, Giovanni, additional, Drexel, Heinz, additional, Emdin, Michele, additional, Farmakis, Dimitros, additional, Halle, Martin, additional, Heymans, Stephane, additional, Jaarsma, Tiny, additional, Jankowska, Ewa, additional, Lainscak, Mitja, additional, Lam, Carolyn S.P., additional, Løchen, Maja‐Lisa, additional, Lopatin, Yuri, additional, Maggioni, Aldo, additional, Matrone, Benedetta, additional, Metra, Marco, additional, Noonan, Katharine, additional, Pina, Ileana, additional, Prescott, Eva, additional, Rosano, Giuseppe, additional, Seferovic, Petar M., additional, Sliwa, Karen, additional, Stewart, Simon, additional, Uijl, Alicia, additional, Vaartjes, Ilonca, additional, Vermeulen, Roel, additional, Monique Verschuren, W. M., additional, Volterrani, Maurizio, additional, von Haehling, Stephan, additional, and Hoes, Arno, additional
- Published
- 2022
- Full Text
- View/download PDF
48. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
- Author
-
Piepoli, Massimo F, primary, Adamo, Marianna, additional, Barison, Andrea, additional, Bestetti, Reinaldo B, additional, Biegus, Jan, additional, Böhm, Michael, additional, Butler, Javed, additional, Carapetis, Jonathan, additional, Ceconi, Claudio, additional, Chioncel, Ovidiu, additional, Coats, Andrew, additional, Crespo-Leiro, Maria G, additional, de Simone, Giovanni, additional, Drexel, Heinz, additional, Emdin, Michele, additional, Farmakis, Dimitros, additional, Halle, Martin, additional, Heymans, Stephane, additional, Jaarsma, Tiny, additional, Jankowska, Ewa, additional, Lainscak, Mitja, additional, Lam, Carolyn S P, additional, Løchen, Maja-Lisa, additional, Lopatin, Yuri, additional, Maggioni, Aldo, additional, Matrone, Benedetta, additional, Metra, Marco, additional, Noonan, Katharine, additional, Pina, Ileana, additional, Prescott, Eva, additional, Rosano, Giuseppe, additional, Seferovic, Petar M, additional, Sliwa, Karen, additional, Stewart, Simon, additional, Uijl, Alicia, additional, Vaartjes, Ilonca, additional, Vermeulen, Roel, additional, Verschuren, W M, additional, Volterrani, Maurizio, additional, Von Haehling, Stephan, additional, and Hoes, Arno, additional
- Published
- 2022
- Full Text
- View/download PDF
49. Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial
- Author
-
Arutyunov, Gregory P., primary, Lopatin, Yuri M., additional, Ametov, Aleksandr S., additional, Ageev, Fail T., additional, Antsiferov, Mikhail B., additional, Villevalde, Svetlana V., additional, Vinogradova, Nadezhda G., additional, Galstyan, Gagik R., additional, Galyavich, Albert S., additional, Gilyarevskiy, Sergey R., additional, Glezer, Maria G., additional, Zhirov, Igor V., additional, Ilyin, Mikhail V., additional, Lebedeva, Anastasiya Iu., additional, Nedogoda, Sergey M., additional, Salukhov, Vladimir V., additional, Tarlovskaya, Ekaterina I., additional, Tereshchenko, Sergey N., additional, Fomin, Igor V., additional, Khalimov, Iurii Sh., additional, Khasanov, Niaz R., additional, Cherkashin, Dmitriy V., additional, and Yakushin, Sergey S., additional
- Published
- 2021
- Full Text
- View/download PDF
50. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction
- Author
-
Seferović, Petar M., primary, Polovina, Marija, additional, Adlbrecht, Christopher, additional, Bělohlávek, Jan, additional, Chioncel, Ovidiu, additional, Goncalvesová, Eva, additional, Milinković, Ivan, additional, Grupper, Avishay, additional, Halmosi, Róbert, additional, Kamzola, Ginta, additional, Koskinas, Konstantinos C., additional, Lopatin, Yuri, additional, Parkhomenko, Alexander, additional, Põder, Pentti, additional, Ristić, Arsen D., additional, Šakalytė, Gintarė, additional, Trbušić, Matias, additional, Tundybayeva, Meiramgul, additional, Vrtovec, Bojan, additional, Yotov, Yoto T., additional, Miličić, Davor, additional, Ponikowski, Piotr, additional, Metra, Marco, additional, Rosano, Giuseppe, additional, and Coats, Andrew J.S., additional
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.